§ Mr. RobathanTo ask the Secretary of State for Health if he will make a statement on the availability of Infliximab for prescription on the NHS for the treatment of Crohn's disease. [101322]
§ Mr. DenhamA European licence was granted on 13 August 1999 for Remicade, whose active constituent is infliximab, for certain indications. These are: for the treatment of severe, active Crohn's disease in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; and for the treatment of fistulising Crohn's disease in patients who have not responded despite a full and adequate course of therapy with conventional treatment.